Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-40 · 6 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SGN-40 | DRUG | 1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12. |
| rituximab | DRUG | 375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8. |
| gemcitabine | DRUG | 1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles. |
| lenalidomide | DRUG | Up to 25 mg daily of a 21-day cycle. |
| dexamethasone | DRUG | 40 mg administered weekly. |
| SGN-40 (anti-huCD40 mAb) | DRUG | 1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6. |
Inclusion Criteria: * Diagnosis of DLBCL. * Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent. * Progression or relapse since most recent therapy. * At least one measurable lesion that is both greater than or equal to 2 cm by conventional C...
SGN-40 is an investigational oncology drug being studied for multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and non-Hodgkin lymphoma. It is a small molecule developed by Pfizer, Inc. (NYSE: PFE). SGN-40 is not FDA approved and remains in clinical development.
SGN-40 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in the oncology therapeutic area, studied for blood cancers including multiple myeloma and lymphoma.
SGN-40 is in Phase 1 clinical development. It has completed two Phase 1 trials and one Phase 2 trial, but no trials are currently active. The drug is investigational and has not received FDA approval.
SGN-40 has completed four clinical trials, including NCT00079716 in refractory or recurrent multiple myeloma, NCT00435916 in relapsed diffuse large B-cell lymphoma, NCT00525447 combining SGN-40 with lenalidomide and dexamethasone in multiple myeloma, and NCT00655837 combining SGN-40 with rituximab and gemcitabine in DLBCL.
SGN-40 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a small molecule being studied for multiple myeloma and various lymphomas, developed by Pfizer, Inc.